Fig. 1
From: Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2
Host cell entry and antibody evasion by SARS-CoV-2 B.1.640.2. a Schematic illustration of the SARS-CoV-2 S protein. Mutations found in the S protein of B.1.640.2 (EPI_ISL_7314471) are highlighted in red. RBD receptor-binding domain, TD transmembrane domain. b Location of the amino acid changes in the trimeric S protein. c Cell lines were inoculated with particles bearing the indicated S proteins. Entry efficiency was analyzed by measuring the activity of virus-encoded luciferase in cell lysates. The average (mean) data ± SEM from six to nine independent experiments are shown; entry driven by the B.1 S protein was set as 1. d 293T cells expressing the indicated S protein (or no S protein) were incubated with soluble ACE2 and secondary antibody and analyzed by flow cytometry. Cells incubated with secondary antibodies alone served as controls. The average ± SD geometric mean channel fluorescence from six biological replicates is shown. e Particles harboring the indicated S proteins were preincubated with soluble ACE2 before being inoculated into Vero cells. The average (mean) data ± SEM from three biological replicates are shown. f Particles bearing the indicated S proteins were incubated with the indicated monoclonal antibody or medium only (control) before being added to Vero cells. Pseudotype entry efficiency was normalized against the respective control (set as 0% inhibition). The average (mean) data ± SEM from three independent experiments are presented. Curves were calculated using a nonlinear regression model (variable slope). g Particles bearing the indicated S proteins were incubated with convalescent plasma or medium only (control) before being added to Vero cells. Pseudotype entry was normalized against the respective control (set as 0% inhibition, please see Supplementary Fig. S2a for individual data). Furthermore, the neutralizing titer that reduced pseudotype entry by 50% (NT50) was calculated. The combined data for ten convalescent sera are presented. Black lines and numerical values indicate the median NT50. h, i The experiment was performed as described in panel g except that plasma from vaccinated individuals was analyzed (panel h: BNT162b2/BNT162b2, n = 10; panel i: BNT162b2/BNT162b2/BNT162b2, n = 10; please see Supplementary Fig. S2b, c for individual data)
